The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.

Daily LSMean estimates of the FLU‐PRO total score during the first 7 days of the RSV‐ARI episode showed a trend (i.e., numerical difference) for participants to recover more rapidly from their symptoms in the RSVPreF3 OA group compared with the Placebo group (Figure S2 ).

also in 53,322 other papers

The observed reduction in symptoms translated into numerical differences in reduced impact of RSV‐ARI on PF that did not reach statistical significance.

also in 111,027 other papers